首页> 外文期刊>European review for medical and pharmacological sciences. >Improvement of the survival and therapeutic effects of implanted mesenchymal stem cells in a rat model of coronary microembolization by rosuvastatin treatment
【24h】

Improvement of the survival and therapeutic effects of implanted mesenchymal stem cells in a rat model of coronary microembolization by rosuvastatin treatment

机译:罗苏伐他汀治疗改善植入间充质干细胞植入间充质干细胞的存活率和治疗效果

获取原文
           

摘要

OBJECTIVE: As the impairment of myocardial micro-environments with local inflammatory reactions due to coronary micro-embolization (CME) reduces the survival of transplanted stem cells (SCs). We hypothesized that rosuvastatin treatment could improve the SC survival and enhance their therapeutic effects. MATERIALS AND METHODS: Rat bone marrow-derived mesenchymal stem cells (BMSCs) were infected with lentivirus carrying the green fluorescent protein (GFP) gene. To develop a CME model, rats were injected with a suspension of microthrombotic particles (MTPs) into the left ventricle to obstruct the ascending aorta. GFP-BMSCs were injected with MTPs simultaneously. Rosuvastatin treatment was started 7 days before BMSC transplantation and ended 7 days after transplantation. RESULTS: Expressions of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were examined by the molecular methods. GFP-positive BMSCs were detected by fluorescence staining. Neovascularization was determined by immunohistochemistry. Myocardial morphology was identified by H&E and Masson’s trichrome staining. Cardiac function was quantified by echocardiography. Three days after CME, the multifocal myocardial necrosis with extensive infiltration of inflammatory cells was observed, accompanied by high expression of TNF-α and IL-1β. Rosuvastatin treatment reduced the infiltration of inflammatory cells and TNF-α and IL-1β expression. 28 days after transplantation, BMSC therapy with rosuvastatin promoted the survival of implanted cells by ≈45-fold while compared with BMSC therapy alone. BMSC therapy with rosuvastatin (instead of BMSC therapy alone) upregulated the VEGF and bFGF expression, increased the capillary density and improved the cardiac function. CONCLUSIONS: These data suggested that rosuvastatin treatment promoted the survival of transplanted SCs and enhanced their therapeutic effects for CME.
机译:目的:由于冠状动脉微栓塞(CME)引起的局部炎症反应的心肌微环境减少(CME)减少了移植干细胞(SCS)的存活率。我们假设罗苏伐他汀治疗可以改善SC存活率,增强其治疗效果。材料和方法:用携带绿色荧光蛋白(GFP)基因的慢病毒感染大鼠骨髓衍生的间充质干细胞(BMSC)。为了开发CME模型,将大鼠用微骨髓颗粒(MTP)的悬浮液注入左心室以阻塞升序主动脉。 GFP-BMSCs同时用MTP注射。在BMSC移植前7天开始Rosuvastatin治疗,移植后7天结束。结果:通过分子方法检查肿瘤坏死因子(TNF)-α,白细胞介素(IL)-1β,血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(BFGF)的表达。通过荧光染色检测GFP阳性BMSCs。通过免疫组织化学确定新生血管化。 H&E和Masson的三色染色鉴定了心肌形态。通过超声心动图量化心脏功能。 CME三天后,观察到具有大量炎症细胞浸润的多焦点心肌坏死,伴随着TNF-α和IL-1β的高表达。罗苏伐他汀治疗减少了炎症细胞和TNF-α和IL-1β表达的渗透。移植后28天,与单独的BMSC疗​​法相比,用罗苏伐他汀的BMSC治疗通过≈45折来促进植入细胞的存活。 BMSC治疗用roosuvastatIN(代替BMSC治疗)上调了VEGF和BFGF表达,增加了毛细血管密度并改善了心功能。结论:这些数据表明,罗苏伐他汀治疗促进移植的SCS的存活率,增强了其对CME的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号